Cytokinetics Set to Unveil Phase 3 Trial Results for Aficamten in Non-Obstructive HCM
Event summary
- Cytokinetics to announce topline results from ACACIA-HCM Phase 3 trial on May 5, 2026.
- Trial evaluates aficamten in non-obstructive hypertrophic cardiomyopathy (HCM) patients.
- Conference call scheduled for 8:00 AM Eastern Time to discuss findings.
- Aficamten is already approved for obstructive HCM under the brand name MYQORZO®.
The big picture
Cytokinetics' ACACIA-HCM trial results are critical for expanding aficamten's therapeutic reach beyond obstructive HCM. Success could position the drug as a leading treatment in the non-obstructive HCM space, a market with significant unmet needs. The outcome will also influence investor confidence in Cytokinetics' broader pipeline of cardiac muscle-targeting therapies.
What we're watching
- Regulatory Pathway
- Whether positive results could expedite aficamten's approval for non-obstructive HCM, expanding its market potential.
- Competitive Positioning
- How these results compare to existing treatments for non-obstructive HCM and Cytokinetics' ability to differentiate aficamten.
- Pipeline Momentum
- The pace at which Cytokinetics advances its other cardiac myosin inhibitors, omecamtiv mecarbil and ulacamten, following this trial.
Related topics